Mineralocorticoid receptor (MR) activation is involved in propagating kidney injury,
inflammation, and fibrosis and in the progression of chronic kidney disease (CKD). Multiple …

The recent successful demonstrations that the nonsteroidal mineralocorticoid receptor (MR)
antagonist finerenone provides effective kidney and cardiovascular (CV) protection in …

Introduction: Proteinuria is a major risk factor for the progression of chronic kidney disease
(CKD). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) demonstrated a …

High circulating levels of fibroblast growth factor-23 (FGF23) are associated with left
ventricular hypertrophy as well as increased morbidity and mortality in patients suffering …

The past 90 years have witnessed an extraordinary trajectory of scientific discovery relating
to aldosterone and mineralocorticoid receptor (MR) activation, and a profound reappraisal of …

Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone produced mainly in
osteocytes. In chronic kidney disease (CKD) FGF23 levels increase due to higher …

Background Biomarkers of chronic kidney disease–mineral and bone disorder (CKD-MBD)
have been implicated in CKD progression in follow-up studies focusing on single …

Patients with primary aldosteronism (PA) are more susceptible to cardiovascular disease
and mortality than patients with primary hypertension. This is mostly attributed to excess …

Klotho plays a critical role in the regulation of ion and fluid homeostasis. A previous study
reported that haplo-insufficiency of Klotho in mice results in increased aldosterone synthase …

Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone produced mainly in
osteocytes. In chronic kidney disease (CKD) FGF23 levels increase due to higher …